Ghaneya graduated from Qatar University with a Bachelor of Science in Biomedical Sciences in 2006. She received a Qatar Research Leadership Program (QRLP) scholarship from the Qatar National Research Fund (QNRF) in 2016 to pursue her postgraduate education. She holds a Master's and PhD in Biological and Biomedical Sciences from Hamad Bin Khalifa University. Her PhD project focused on exploring the role of cancer testis antigen PRAME in the oncogenesis and tumor progression of breast cancer. She joined Dr. Lawrence Stanton’s team in 2021 as a Senior Research Associate and she is involved in various projects exploring the molecular mechanisms and pathways underlying neurodevelopmental disorders, including Autism Spectrum Disorder (ASD).
Neurological Disorders Research Center; Qatar Biomedical Research Institute-Research Development Center; HBKU.
2021 - PresentQatar Foundation Research and Development
2016 - 2021Department of Laboratory Medicine and Pathology; Hamad Medical Corporation.
2012 - 2016Department of Laboratory Medicine and Pathology; Hamad Medical Corporation.
2007 - 2012College of Health and Life Sciences; Hamad Bin Khalifa University-Qatar Foundation; Doha-Qatar.
2021College of Health and Life Sciences; Hamad Bin Khalifa University-Qatar Foundation; Doha-Qatar.
2017Department of Health Sciences-College of Arts and Sciences; Qatar University; Doha-Qatar.
2006PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med 17 (2019): 1–14.
2019Cancertestisantigensandimmunotherapy:Where do we stand in the targeting of PRAME? Cancers (Basel)11 (2019): 1–14.
2019Cancer testis antigen PRAME: an-anti cancer target with immunomodulatory potential. JCMM (2021).
2021Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front. Oncol. 10 (2021).
2021NY-ESO-1 based immunotherapy of cancer: Current perspectives. Front. Immunol. 9 (2018).
2018